Table 3

Cross tabulation of disorders, size of sample, source of support, pharmaceutical agents and outcome of papers with Jadad Index above 2

Jadad Index > 2 (N = 10)









N of papers
Year
Jadad Index
P N W
N of patients
Financial support
Drug dose (mg/day)

Risperidone (N = 7)








Substance abuse
1
2000
3
0 1 0
125
I
2–8
OCD
1
2000
5
1 0 0
36
I
2.2
Pervasive Developmental disorder
3
1998, 2001, 2001
5, 3, 3
3 0 0
31, 38, 13
I, P, P
2.9, 2.9, 1.2
Stuttering
1
1999
3
1 0 0
21
I
<2
Tourette's syndrome
1
2001
5
1 0 0
50
P
3.8

Olanzapine (N = 3)








Depression
1
2001
3
1 0 0
28
P
12.5–13.5
Personality disorder
1
2001
5
1 0 0
28
P
5.33
Post Traumatic Stress disorder
1
2001
3
0 1 0
15
P
14.1
Quetiepine (N = 0)
0
-
-
-
-
-
-

P = improvement of the patients, N = no change, W = worsening of the patients I: supported by State or independent grants P: supported by a pharmaceutical company